TDC
IGC icon

Thompson Davis & Co’s IGC Pharma IGC Stock Holding History

Thompson Davis & Co’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$4.17K – 170
2025
Q3 		$4.17K Buy
+10,000
New +$3.8K ﹤0.01% 148
2018
Q1 		– Sell
-10,000
Closed -$10K – 670
2017
Q4 		$10K Buy
+10,000
New +$5.53K 0.02% 413

Other funds holding IGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM

Thompson Davis & Co's IGC Position: Q4 2025 in Review

Thompson Davis & Co sold out of IGC Pharma (IGC) in Q4 2025, closing a stake of 10,000 shares — an estimated $4.17K sold.

Thompson Davis & Co first reported a position in IGC in Q4 2017 and held it in 2 quarters. The position peaked at $10K in Q4 2017. 30 funds tracked by Wall St. Rank hold IGC as of Q4 2025.

  • Thompson Davis & Co reported no remaining IGC Pharma position as of Q4 2025 after selling out during the quarter.
  • Thompson Davis & Co sold 10,000 IGC Pharma shares in Q4 2025, an estimated $4.17K.
  • Thompson Davis & Co first reported a position in IGC Pharma in Q4 2017 and held it in 2 quarters.
  • Thompson Davis & Co's IGC Pharma position peaked at $10K in Q4 2017.
  • 30 funds tracked by Wall St. Rank held IGC Pharma as of Q4 2025.

Based on Thompson Davis & Co's 13F filing for Q4 2025, filed 12 Jan 2026.